This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Baxter International Hiding in Plain Sight

The medical conglomerate Baxter International (BAX - Get Report) looked like a swooning biotech when its stock lost two-thirds of its value between March 2002 and March 2003.

Since then, Baxter has acted like booming biotech. Its stock has more than tripled in the past five years, easily outperforming the S&P 500 and the Amex Index of large drug stocks.

Also during this period, Baxter has driven its mixture of medications and devices well past the stock showings of health care hybrids like Johnson & Johnson (JNJ - Get Report) and Abbott (ABT - Get Report).

And at a time when defensive health care stocks aren't feeling well, Baxter gained about 10% for the 12 months ended June 11, comfortably ahead of Abbott and slightly ahead of J&J. The S&P 500 was down more than 10%, while the Amex drug index fell more than 23%.

"Baxter offers the high predictive value that investors in this increasingly volatile market environment desire," says a recent report by Ben Andrew of William Blair & Co., as he raised his rating to outperform from market perform. Baxter benefits from a "diversified, defensible product portfolio," says Andrew, who doesn't own shares.

First-quarter sales rose 8% and earnings per share gained 10% vs. the same period last year, heralding the 14th consecutive quarter in which Baxter beat Wall Street estimates, says a recent Bear Stearns report. Baxter raised its full-year earnings-per-share forecast, excluding special items, to a range of $3.18 to $3.24 from a previous estimate of $3.10 to $3.18.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $37.41 0.00%
BAX $37.49 0.00%
JNJ $100.54 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs